A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma

Full Title

204653: A Phase I, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects with Solid Tumors and Non-Hodgkin’s Lymphoma

Purpose

The purpose of this study is to find an effective dose of a new drug that can be given safely in patients with solid tumors and non-Hodgkin lymphoma that have continued to grow despite standard treatment. This “epigenetic-modifying” drug works by altering proteins that may affect genes responsible for cancer growth. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a solid tumor or non-Hodgkin lymphoma that cannot be cured with standard therapy.
  • Patients must recover from the serious side effects of previous therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Mrinal Gounder at 646-888-4167.

Protocol

17-188

Phase

I

Investigator

Co-Investigators